Ibandronic acid
Ibandronic acid (Bondronat) is a bisphosphonate available in Europe as a monthly infusion or daily tablet to prevent fractures and other bone complications in women with breast cancer that has spread to bone, and to treat cancer-related high calcium.
Overview
Ibandronic acid was authorised by the European Commission in June 1996 for tumour-induced hypercalcaemia and later for prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases, on placebo-controlled trials of intravenous 6 mg every three to four weeks and oral 50 mg daily that reduced skeletal morbidity. It is the only bisphosphonate with an oral formulation licensed for bone metastases; in the US ibandronate (Boniva) is approved for osteoporosis only. The ZICE trial found oral ibandronate slightly less effective than zoledronic acid for skeletal events, so guidelines list it as an alternative. Renal toxicity is lower than with zoledronic acid; osteonecrosis of the jaw and oesophageal irritation with tablets are the recognised risks. Originated by Roche.
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 1996 | Tumour-induced hypercalcaemia; prevention of skeletal events in breast cancer with bone metastases (Bondronat) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Ibandronic acid" OR ABSTRACT:"Ibandronic acid" OR TITLE:"Bondronat" OR ABSTRACT:"Bondronat" OR TITLE:"Ibandronate" OR ABSTRACT:"Ibandronate" OR TITLE:"Boniva osteoporosis formulation" OR ABSTRACT:"Boniva osteoporosis formulation" OR TITLE:"Bonviva" OR ABSTRACT:"Bonviva") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ibandronic acid, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductPamidronate
Shares Zoledronic acid, Denosumab, Bone-modifying agents (bisphosphonates, denosumab), HR-positive / HER2-negative breast cancer and the tag supportive.
- ProductSamarium-153 lexidronam
Shares HR-positive / HER2-negative breast cancer and the tags ema-list, supportive.
- ProductCatumaxomab
Shares the tags ema-list, supportive.
- ProductEfbemalenograstim alfa
Shares the tags ema-list, supportive.
- ProductLipegfilgrastim
Shares the tags ema-list, supportive.
- ProductTelotristat ethyl
Shares the tags ema-list, supportive.
- ProductThyrotropin alfa
Shares the tags ema-list, supportive.
- TargetRANK ligand (RANKL)
Shares Denosumab, Bone-modifying agents (bisphosphonates, denosumab), HR-positive / HER2-negative breast cancer.